DAFZ eyes growing pharmacy market
Dubai, April 20, 2009
Dubai Airport Free Zone (DAFZ), home to multinational pharmaceutical firms in the UAE, is taking part in a major pharmaceutical show aiming to expand on its sales and marketing activities, said a top DAFZ official.
Pharmaceutical and Biotechnology Middle East (PABME) 2009 opened today (April 20) at Dubai International Convention and Exhibition Centre, and will run until April 22.
PABME estimates that the combined pharmaceutical sales revenue in the markets of North Africa, the Levant states and Iran as well as the newer markets of the GCC countries (Saudi Arabia, Kuwait, Bahrain, Oman, Qatar and the UAE) is valued at more than Dh44 billion (US$12 billion) and is estimated to be growing at an annual rate of over 10 per cent.
Research has further shown that in the Middle East there is an estimated to be more than 450 pharmaceutical manufacturers – a figure that is growing dramatically year on year.
Ibrahim Ahli, marketing director DAFZ, said: “It is the first time that we've exhibited in PABME 2009 and we're definitely looking forward to expand on our sales and marketing activities.”
“This is a market that the Freezone is keen to attract,” he added.
DAFZ has been participating in quite a number of specialised exhibitions which help the free zone attract multinational companies.
“PABME 2009 is an exciting stage to network and discuss business,” Ali said.
“Our strategy in PABME 2009 is to increase our opportunities to attract and communicate with pharmaceutical companies to set up offices and invest in the Middle East in general and the UAE in particular.
'The pharmaceutical and biotechnology sectors are growing at such an incredible rate in the region. Several international companies are participating in this large event that it would give us a chance to meet the market leaders and new investors across the globe.”
“Sales department representatives at the free zone will be present at the stand to address visitors’ inquiries and needs with all information and data that would be of interest to pharmaceutical and biotechnological companies,” Ahli added. – TradeArabia News Service